ID   Ramos
AC   CVCL_0597
SY   RAMOS; Ramos 1; RA 1; RA.1; Ra #1; Ra No. 1; Ramos(RA1); Ramos-RA1; Ramos (RA 1); Ramos (RA #1); Ramos (RA)
DR   BTO; BTO_0003079
DR   CLO; CLO_0008738
DR   CLO; CLO_0008739
DR   EFO; EFO_0002077
DR   MCCL; MCC:0000410
DR   CLDB; cl4096
DR   CLDB; cl4097
DR   CLDB; cl4098
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-1596
DR   BCRC; 60252
DR   BEI_Resources; ARP-9938
DR   BioGRID_ORCS_Cell_line; 151
DR   BioSample; SAMN01821590
DR   BioSample; SAMN01821657
DR   BioSample; SAMN03472718
DR   cancercelllines; CVCL_0597
DR   CCRID; 1101HUM-PUMC000048
DR   CCRID; 1102HUM-NIFDC00052
DR   Cell_Model_Passport; SIDM01094
DR   CGH-DB; 9205-4
DR   ChEMBL-Cells; CHEMBL3307664
DR   ChEMBL-Targets; CHEMBL614629
DR   CLS; 302007
DR   Cosmic; 929817
DR   Cosmic; 931111
DR   Cosmic; 991547
DR   Cosmic; 998719
DR   Cosmic; 1037704
DR   Cosmic; 1226864
DR   Cosmic; 1509204
DR   Cosmic; 1517660
DR   Cosmic; 1762459
DR   Cosmic; 1818347
DR   Cosmic; 2750875
DR   Cosmic; 2759408
DR   Cosmic; 2814542
DR   Cosmic; 2823075
DR   DepMap; ACH-001636
DR   DSMZ; ACC-603
DR   DSMZCellDive; ACC-603
DR   ECACC; 85030802
DR   ECACC; 91030710
DR   EGA; EGAS00001000610
DR   FCS-free; 243-2-490-3-4-12
DR   GEO; GSM99388
DR   GEO; GSM987747
DR   GEO; GSM987748
DR   GEO; GSM987749
DR   GEO; GSM1374843
DR   GEO; GSM1374844
DR   GEO; GSM3150254
DR   IARC_TP53; 180
DR   JCRB; JCRB9119
DR   KCLB; 21596
DR   LINCS_HMS; 50811
DR   LINCS_LDP; LCL-1097
DR   Lonza; 725
DR   NCBI_Iran; C128
DR   PharmacoDB; RAMOS_1283_2019
DR   PRIDE; PXD000447
DR   PRIDE; PXD012087
DR   PubChem_Cell_line; CVCL_0597
DR   Wikidata; Q54949198
RX   PubMed=62724;
RX   PubMed=175026;
RX   PubMed=181343;
RX   PubMed=1850347;
RX   PubMed=1915267;
RX   PubMed=2052620;
RX   PubMed=2835030;
RX   PubMed=2985879;
RX   PubMed=2998993;
RX   PubMed=3026973;
RX   PubMed=3159941;
RX   PubMed=3518877;
RX   PubMed=3874327;
RX   PubMed=6231253;
RX   PubMed=6286763;
RX   PubMed=7316467;
RX   PubMed=7757991;
RX   PubMed=8316623;
RX   PubMed=8344493;
RX   PubMed=8402660;
RX   PubMed=8515068;
RX   PubMed=8896424;
RX   PubMed=9192833;
RX   PubMed=9225077;
RX   PubMed=9473234;
RX   PubMed=9563901;
RX   PubMed=9973220;
RX   PubMed=10739008;
RX   PubMed=10918597;
RX   PubMed=11226526;
RX   PubMed=12967475;
RX   PubMed=18211290;
RX   PubMed=20922763;
RX   PubMed=22885699;
RX   PubMed=24590883;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=28196595;
RX   PubMed=31160637;
WW   Info; COPE; -; http://www.cells-talk.com/index.php/page/copelibrary?key=Ramos
WW   Info; MCLP; -; https://tcpaportal.org/mclp/
WW   Info; Thermo Fisher; -; https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/r/cell-lines-detail-485.html
WW   Provider; Altogen; Xenograft model; https://altogenlabs.com/xenograft-models/lymphoma-xenograft/ramos-xenograft-model/
WW   Provider; CCR; -; https://www.cccells.org/cellreqs-ncipptp.php
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Population: Caucasian.
CC   Virology: EBV-negative.
CC   Doubling time: 20.4 +- 1.5 hours (PubMed=9225077); 23 hours (PubMed=8402660); 26 hours (PubMed=9563901); 14 hours (PubMed=20922763); ~48 hours (DSMZ=ACC-603).
CC   HLA typing: A*03:01,03:01; B*44:03,51:01; C*16:01,16:01; DQA1*02:01,02:01; DQB1*02:01,02:01; DRB1*07:01,14:103 (PubMed=25960936).
CC   HLA typing: A*03:01,03:01; B*44:03,51:01; C*16:01,16:01; DQA1*02:01,02:01; DQB1*02:01,02:01; DRB1*07:01,14:05 (PubMed=26589293).
CC   HLA typing: A*03:01:01; B*44:160Q,51:01:01; C*16:01:01; DPB1*04:01:01,104:01:01; DQA1*02:01:01; DQB1*02:02:01; DRB1*07:01:01 (CLS=302007).
CC   HLA typing: A*03:01:01,03:01:01; B*44:03:01,51:01:01; C*16:01:01,16:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,104:01; DQA1*02:01:01,02:01:01; DRA*01:01:01,01:01:01; DRB1*07:01:01,07:01:01 (DSMZCellDive=ACC-603).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526).
CC   Sequence variation: Gene fusion; HGNC; HGNC:5477; IGH + HGNC; HGNC:7553; MYC; Name(s)=MYC-IGH (PubMed=10918597).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (PubMed=1915267; PubMed=2052620; PubMed=8344493).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Proteomics.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): ATCC=CRL-1596; CCRID; CLS=302007; COG; DepMap=ACH-001636; DSMZ=ACC-603; ECACC=85030802; JCRB=JCRB9119; KCLB=21596; PubMed=20922763; PubMed=25877200; Technion Genomics Center
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D10S1248: 14,15
ST   D12S391: 19,22
ST   D13S317: 12,13,14 (CLS=302007)
ST   D13S317: 13,14 (ATCC=CRL-1596; CCRID; COG; DepMap=ACH-001636; DSMZ=ACC-603; ECACC=85030802; JCRB=JCRB9119; KCLB=21596; PubMed=20922763; PubMed=25877200; Technion Genomics Center)
ST   D16S539: 10,13
ST   D18S51: 14,15 (CLS=302007; DSMZ=ACC-603)
ST   D18S51: 15 (ATCC=CRL-1596; CCRID; DepMap=ACH-001636; PubMed=20922763; PubMed=25877200; Technion Genomics Center)
ST   D19S433: 14,15.2
ST   D1S1656: 12,15.3
ST   D21S11: 30
ST   D22S1045: 15
ST   D2S1338: 20,23
ST   D2S441: 11,14
ST   D3S1358: 14,15
ST   D5S818: 7,12
ST   D6S1043: 13,15
ST   D7S820: 11
ST   D8S1179: 13 (CLS=302007)
ST   D8S1179: 13,16 (ATCC=CRL-1596; CCRID; DepMap=ACH-001636; DSMZ=ACC-603; PubMed=20922763; PubMed=25877200; Technion Genomics Center)
ST   FGA: 20,24
ST   Penta D: 10,13
ST   Penta E: 6,8,21 (CLS=302007)
ST   Penta E: 8,21 (ATCC=CRL-1596; CCRID; DepMap=ACH-001636; DSMZ=ACC-603; PubMed=25877200; Technion Genomics Center)
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 15,16
DI   NCIt; C2912; Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   3Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 45
//
RX   PubMed=62724; DOI=10.1002/ijc.2910180513;
RA   Klein G., Zeuthen J., Terasaki P.I., Billing R.J., Honig R., Jondal M.,
RA   Westman A., Clements G.B.;
RT   "Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker
RT   properties of EBV-negative lymphoma lines and their in vitro
RT   EBV-converted sublines.";
RL   Int. J. Cancer 18:639-652(1976).
//
RX   PubMed=175026; DOI=10.1002/ijc.2910170203;
RA   Fresen K.-O., zur Hausen H.;
RT   "Establishment of EBNA-expressing cell lines by infection of
RT   Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with
RT   different EBV strains.";
RL   Int. J. Cancer 17:161-166(1976).
//
RX   PubMed=181343; DOI=10.1159/000149930;
RA   Klein G., Giovanella B.C., Westman A., Stehlin J.S. Jr., Mumford D.M.;
RT   "An EBV-genome-negative cell line established from an American Burkitt
RT   lymphoma; receptor characteristics. EBV infectibility and permanent
RT   conversion into EBV-positive sublines by in vitro infection.";
RL   Intervirology 5:319-334(1975).
//
RX   PubMed=1850347; DOI=10.1210/endo-128-5-2266;
RA   Baglia L.A., Cruz D., Shaw J.E.;
RT   "An Epstein-Barr virus-negative Burkitt lymphoma cell line (sfRamos)
RT   secretes a prolactin-like protein during continuous growth in
RT   serum-free medium.";
RL   Endocrinology 128:2266-2272(1991).
//
RX   PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x; PMCID=PMC452998;
RA   Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
//
RX   PubMed=2052620; DOI=10.1073/pnas.88.12.5413; PMCID=PMC51883;
RA   Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A.,
RA   Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.;
RT   "p53 mutations in human lymphoid malignancies: association with
RT   Burkitt lymphoma and chronic lymphocytic leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991).
//
RX   PubMed=2835030; DOI=10.1016/S0385-8146(87)80025-1;
RA   Takimoto T., Sato H., Ogura H., Miyazaki T.;
RT   "Establishment of an Epstein-Barr virus (EBV) genome-positive subline
RT   of Ramos (Ramos/NPC) following infection of Ramos with nasopharyngeal
RT   carcinoma (NPC)-derived EBV.";
RL   Auris Nasus Larynx 14:87-92(1987).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   Carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=2998993;
RA   Steel C.M., Morten J.E.N., Foster E.;
RT   "The cytogenetics of human B lymphoid malignancy: studies in Burkitt's
RT   lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell
RT   lines.";
RL   IARC Sci. Publ. 60:265-292(1985).
//
RX   PubMed=3026973; DOI=10.1002/ijc.2910390215;
RA   Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.;
RT   "Expression of B-cell-specific markers in different Burkitt lymphoma
RT   subgroups.";
RL   Int. J. Cancer 39:211-218(1987).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=6231253; DOI=10.1002/ijc.2910330407;
RA   Ehlin-Henriksson B., Klein G.;
RT   "Distinction between Burkitt lymphoma subgroups by monoclonal
RT   antibodies: relationships between antigen expression and type of
RT   chromosomal translocation.";
RL   Int. J. Cancer 33:459-463(1984).
//
RX   PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336;
RA   Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd-Kulikowsk H.D.,
RA   Parsons R.G.;
RT   "Immunoglobulin secretion by cell lines derived from African and
RT   American undifferentiated lymphomas of Burkitt's and non-Burkitt's
RT   type.";
RL   J. Immunol. 129:1336-1342(1982).
//
RX   PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x;
RA   Povey S., Jeremiah S., Arthur E., Steel M., Klein G.;
RT   "Differences in genetic stability between human cell lines from
RT   patients with and without lymphoreticular malignancy.";
RL   Ann. Hum. Genet. 44:119-133(1980).
//
RX   PubMed=7757991;
RA   Bae I., Fan S.-J., Bhatia K.G., Kohn K.W., Fornace A.J. Jr.,
RA   O'Connor P.M.;
RT   "Relationships between G1 arrest and stability of the p53 and
RT   p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma
RT   cells.";
RL   Cancer Res. 55:2387-2393(1995).
//
RX   PubMed=8316623; DOI=10.2307/3578190;
RA   Evans H.H., Ricanati M., Horng M.-F., Jiang Q.-Y., Mencl J.,
RA   Olive P.L.;
RT   "DNA double-strand break rejoining deficiency in TK6 and other human
RT   B-lymphoblast cell lines.";
RL   Radiat. Res. 134:307-315(1993).
//
RX   PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493;
RA   Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R.,
RA   Magrath I.T.;
RT   "Hemi- or homozygosity: a requirement for some but not other p53
RT   mutant proteins to accumulate and exert a pathogenetic effect.";
RL   FASEB J. 7:951-956(1993).
//
RX   PubMed=8402660;
RA   O'Connor P.M., Jackman J., Jondle D., Bhatia K.G., Magrath I.T.,
RA   Kohn K.W.;
RT   "Role of the p53 tumor suppressor gene in cell cycle arrest and
RT   radiosensitivity of Burkitt's lymphoma cell lines.";
RL   Cancer Res. 53:4776-4780(1993).
//
RX   PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418;
RA   Jain V.K., Judde J.-G., Max E.E., Magrath I.T.;
RT   "Variable IgH chain enhancer activity in Burkitt's lymphomas suggests
RT   an additional, direct mechanism of c-myc deregulation.";
RL   J. Immunol. 150:5418-5428(1993).
//
RX   PubMed=8896424; DOI=10.1182/blood.V88.9.3562.bloodjournal8893562;
RA   Chapman C.J., Zhou J.X., Gregory C.D., Rickinson A.B., Stevenson F.K.;
RT   "VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic
RT   hypermutation, intraclonal heterogeneity, and a role for antigen
RT   selection.";
RL   Blood 88:3562-3568(1996).
//
RX   PubMed=9192833;
RA   Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H.S.,
RA   Pike S.E., Gupta G., Magrath I.T., Tosato G.;
RT   "Role of the p53 tumor suppressor gene in the tumorigenicity of
RT   Burkitt's lymphoma cells.";
RL   Cancer Res. 57:2508-2515(1997).
//
RX   PubMed=9225077; DOI=10.1016/S0145-2126(97)00126-4;
RA   Okano M.;
RT   "High susceptibility of an Epstein-Barr virus-converted Burkitt's
RT   lymphoma cell line to cytotoxic drugs.";
RL   Leuk. Res. 21:469-471(1997).
//
RX   PubMed=9473234; DOI=10.1182/blood.V91.5.1680;
RA   Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.;
RT   "p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a
RT   mRNA and protein expression in Burkitt's lymphoma.";
RL   Blood 91:1680-1687(1998).
//
RX   PubMed=9563901;
RA   Fan S.-J., Cherney B.W., Reinhold W.C., Rucker K., O'Connor P.M.;
RT   "Disruption of p53 function in immortalized human cells does not
RT   affect survival or apoptosis after taxol or vincristine treatment.";
RL   Clin. Cancer Res. 4:1047-1054(1998).
//
RX   PubMed=9973220;
RA   Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G.,
RA   Magrath I.T., Bhatia K.G.;
RT   "Bax is frequently compromised in Burkitt's lymphomas with
RT   irreversible resistance to Fas-induced apoptosis.";
RL   Cancer Res. 59:696-703(1999).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=10918597; DOI=10.1038/sj.onc.1203686;
RA   Bemark M., Neuberger M.S.;
RT   "The c-MYC allele that is translocated into the IgH locus undergoes
RT   constitutive hypermutation in a Burkitt's lymphoma line.";
RL   Oncogene 19:3404-3410(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000), 255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x; PMCID=PMC11160262;
RA   Maesako Y., Uchiyama T., Ohno H.;
RT   "Comparison of gene expression profiles of lymphoma cell lines from
RT   transformed follicular lymphoma, Burkitt's lymphoma and de novo
RT   diffuse large B-cell lymphoma.";
RL   Cancer Sci. 94:774-781(2003).
//
RX   PubMed=18211290; DOI=10.1111/j.1365-2184.2007.00500.x; PMCID=PMC6495949;
RA   Zander Balderud L., Bemark M.;
RT   "Identification of genes deregulated during serum-free medium
RT   adaptation of a Burkitt's lymphoma cell line.";
RL   Cell Prolif. 41:136-155(2008).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801; PMCID=PMC3005554;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=22885699; DOI=10.1038/nature11378; PMCID=PMC3609867;
RA   Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L.,
RA   Wright G., Shaffer A.L. 3rd, Hodson D.J., Buras E., Liu X.-L., Powell J.I.,
RA   Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.M.,
RA   Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M.,
RA   Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B.,
RA   Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.-C., Pittaluga S., Wilson W.,
RA   Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.;
RT   "Burkitt lymphoma pathogenesis and therapeutic targets from structural
RT   and functional genomics.";
RL   Nature 490:116-120(2012).
//
RX   PubMed=24590883; DOI=10.1002/gcc.22161;
RA   Murga Penas E.-M., Schilling G., Behrmann P., Klokow M.,
RA   Vettorazzi E., Bokemeyer C., Dierlamm J.;
RT   "Comprehensive cytogenetic and molecular cytogenetic analysis of 44
RT   Burkitt lymphoma cell lines: secondary chromosomal changes
RT   characterization, karyotypic evolution, and comparison with primary
RT   samples.";
RL   Genes Chromosomes Cancer 53:497-515(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218.1-8218.14(2019).
//